Use of aromatase inhibitors in children with short stature

Pediatric Endocrinology Reviews

Volumn 2, Issue 1, 2004, Pages 2-7

  Cernich, Joseph ^a,b   Jacobson, Jill D ^a   Moore, Wayne V ^a   Popovic, Jadranka ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Aromatase inhibitors; Bone age; Short stature

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; APOLIPOPROTEIN B; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; EXEMESTANE; FLUDROCORTISONE; FLUTAMIDE; FORMESTANE; HYDROCORTISONE; LETROZOLE; LOW DENSITY LIPOPROTEIN; PLACEBO; TESTOLACTONE; TESTOSTERONE;

ACNE; ADRENAL FUNCTION; ALBRIGHT SYNDROME; BODY HEIGHT; BONE AGE; BONE DENSITY; BONE MATURATION; BREAST CARCINOMA; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; DELAYED PUBERTY; DRUG EFFICACY; DRUG SAFETY; ESTROGEN SYNTHESIS; HUMAN; LIPID METABOLISM; REVIEW; SHORT STATURE; SIDE EFFECT; WEIGHT GAIN;

ADULT; AMINOGLUTETHIMIDE; ANDROSTENEDIONE; AROMATASE INHIBITORS; BODY HEIGHT; CHILD; ESTROGENS; FEMALE; GROWTH DISORDERS; HUMANS; MALE; MUSCULOSKELETAL SYSTEM; NITRILES; TRIAZOLES;

EID: 12444317672     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Bilezikian JP, Khosla S, Riggs BL. Estrogen effects on bone in the male skeleton. In: Bilezikian JP RL, Rodan GA, editor. Principles of Bone Biology. 2nd ed. San Diego, CA: Academic Press; 2002:1467-1476
2. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. The Journal of Clinical Endocrinology and Metabolism 2000;85(7):2370-2377
3. Yanovski J, Rose L, Municchi G, et. al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. New England Journal of Medicine 2003(348):908-17
4. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr. Treatment of precocious puberty in the McCune-Albright Syndrome with the aromatase inhibitor testolactone. New England Journal of Medicine 1986;315(18):1115-1119
5. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism 2003;88(12):5730-33
6. Buzdar AU, Robertson JFR, Eiermann W, Nabholtz J. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002;95:2006-2016
7. Mauras N, Lima J, Patel D, Rini A, DiSalle E, Kwok A, Lippe B. Pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasin (exemestane), in young males. Journal of Clinical Endocrinology and Metabolism 2003;88(12):5951-56
8. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. Journal of Steroid Biochemistry and Molecular Biology 2003(87):35-45
9. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 2002;20:751-757
10. Wickman S, Sipila I, Ankarberg-Lingren C, Norgavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. The Lancet 2001;357:1743-48
11. Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult heights and adrenal gland function. Journal of Pediatric Endocrinology and Metabolism (In press)
12. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999;84:175-178
13. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB. Flutamide, testolactone and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:1114-1120
14. Turpin AL, Popovic J, Karmazin A, Moore WV, Jacobson JD. Aromatase inhibitor may delay skeletal maturation and improve final height in females. In: 86th Annual Endocrine Society Meeting; 2004; New Orleans, LA
15. Demers LM. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat. 1994;30:95-102
16. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA. Effect of letrozole on the lipid in postmenopausal women with breast cancer. European Journal of Cancer 2001;37:1510-1513
17. Bisagni G, Cocconi G, Scaglione F, Fraschini F, Pfister C, Trunet PF. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99-102
18. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L, Martinetti A, Marchiano A, Pozzi P, Stani S, Bichisao E. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. European Journal of Cancer 1999;35:208-213
19. Aquila S, Sisci D, Gentile M, Carpino A, Middea E, Catalano S, Rago V, Ando S. Towards a physiological role for cytochrome P450 aromatase in ejaculated human sperm. Human Reproduction 2003;18(8):1650-1659
20. Gerardin DC, Pereira OC. Reproductive changes in male rats treated perinatally with an aromatase inhibitor. Pharmacol Biochem Behav. 2002;71:301-305
21. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. The Journal of Urology 2001;165:837-841
22. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. The Journal of Clinical Endocrinology and Metabolism 2003;88(8):3785-3793
23. Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. European Journal of Endocrinology 2002;146(3):339-346
24. Morrison JA, Sprecher DL, Biro FM, Apperson-Hansen C, Lucky AW, DiPaola LM. Estradiol and testosterone effects on lipids in black and white boys aged 10 to 15 years. Metabolism 2000;49:11241129
25. Morrison JA, Sprecher DL, Biro FM, Hansen CA, Lucky AW, Wride K. Sex hormones and lipoproteins in adolescent male offspring of parents with premature coronary heart disease and a control group. Journal of Pediatrics 1998;133:526-532
26. Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. The Journal of Clinical Endocrinology and Metabolism 2001;86(10):4887-4894
27. Rochira V. Aromatase inhibitors in pubertal boys: clinical implications (Letter). Journal of Clinical Endocrinology and Metabolism 2001;86(4):1836-1837
28. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 1998;83:1886-1892
29. Mauras N, Hayes V, Yergey AL. Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res. 1999;14:577-582
30. Stanhope R. Use of a specific aromatase inhibitor in delayed puberty. Lancet 2001;357:1723-24
31. Albanese A, Stanhope R. Does constitutional delayed puberty cause segmental disproportion and short stature? Eur J Pediatr 1993(152):293-296
32. Roselli CE, Resko JA. Cytochrome P450 aromatase (CYP19) in the non-human primate brain: distribution, regulation and functional significance. Journal of Steroid Biochemistry & Molecular Biology 2001;79:247-253
33. Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999;6:315-324